Navigation Links
ViroPharma To Acquire Lev Pharmaceuticals
Date:7/15/2008

e data from Lev's acute treatment trial was not presented before the BPAC and is currently under active review at FDA. On May 6, 2008, Lev announced that FDA accepted for review Lev's complete response submission for Cinryze targeting an action date of October 14, 2008.

About Hereditary Angioedema

HAE is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unrestricted, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. While there is no approved therapy for acute HAE attacks in the U.S., a commercially available C1 inhibitor has been used in Europe to treat HAE for more than 35 years. There are estimated to be 10,000 people with HAE in the U.S.

Additional information on HAE can be obtained from the U.S. Hereditary Angioedema Association at http://www.haea.org.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug developme
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ViroPharma to Present at Two Upcoming Healthcare Conferences
2. ViroPharma Provides 2008 Outlook
3. ViroPharma to Present at the BIO CEO & Investor Conference
4. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
11. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... 23, 2014 GMO corn cases filed across ... in the process of being consolidated in a Kansas federal ... Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 in ... Management of the Syngenta GMO corn multidistrict litigation (MDL) has ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 The ... as its definition, classification, application and industry overview. ... and product cost structure. Production is separated by ... upstream raw materials, equipment, downstream client survey, marketing ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... Inverness Medical,Innovations, Inc. (Amex: IMA ) ... dated January 31, 2008 and entitled "Inverness Medical,Innovations ... and Medical Device Conference on February 5, 2008." ... Company,s presentation. The,correct time of the presentation is ...
... Calif., Feb. 1 Edwards Lifesciences,Corporation (NYSE: ... technologies to,treat advanced cardiovascular disease, is scheduled to ... Medical Device,Conference at the Grand Hyatt Hotel in ... M. Abate, Edwards Lifesciences, corporate vice president, chief,financial ...
... Inc.,(Nasdaq: VRUS ) management will be presenting at ... February 11 - 13, 2008 at the,Waldorf-Astoria Hotel in ... provide an overview of the company on Monday,February 11, ... Salon. In,addition, Dr. Michelle Berrey, Pharmasset,s Chief Medical Officer, ...
Cached Biology Technology:Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th 2
(Date:1/22/2015)... Jan. 21, 2015  Analyst Report Issued by Small Cap IR. ... showed that planet-wide, transactions at merchants on the leading payment ... number of credit, debit, and prepaid cards reached 6.54 billion.  ... of fraudulent card usage in 2012, and credit and debit ...
(Date:1/22/2015)... NEW YORK , Jan. 22, 2015   EyeLock, Inc. ... announced it has appointed Steve Gerber to the ... Gerber will be responsible for leading development of mobile platforms ... 25 years of success and innovation in the semiconductor industry ...
(Date:12/22/2014)... Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" or ... mobile commerce market, announces it has retained famous pickpocket, entertainer ... International CES debut of the Wocket™ biometric smart wallet.  ... NXT-ID booth January 6th and 7 th , 2015, demonstrating ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... MD FASEB MARC (Maximizing Access to Research Careers) ... Society for the Study of Reproduction (SSR) Annual Meeting ... These awards are meant to promote the entry of ... of the basic science community and to encourage the ...
... systems work together to paralyze skeletal muscles during rapid eye ... 11 issue of The Journal of Neuroscience . The ... including narcolepsy, tooth grinding, and REM sleep behavior disorder. ... recalled dreams occur your eyes continue to move but ...
... has been awarded a grant expected to total more ... (NIH) National Institute of Allergy and Infectious Diseases (NIAID). ... vaccine against HIV and the disease it causes, AIDS. ... vaccine is urgently needed to slow and eventually eliminate ...
Cached Biology News:Study identifies how muscles are paralyzed during sleep 2Scripps Research Institute wins $77 million to develop AIDS vaccine center 2Scripps Research Institute wins $77 million to develop AIDS vaccine center 3
... The BD FACSAria cell sorter sets a ... Based on a revolutionary new design ... high-speed sorting and multicolor analysis. The BD ... that incorporates a fixed-alignment cuvette flow cell. ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Mouse monoclonal antibody raised against a full length recombinant LDB3. NCBI Entrez Gene ID = LDB3...
Biology Products: